Join The Discussion

 

Ice cancels flights, snarls traffic; snow in North Texas forecast

DALLAS (AP) — More wintry weather was expected across parts of North Texas through Wednesday.

read more >

Riverside: Developer sees revitalization with apartments, townhomes driving commercial projects

A Dallas developer is seeking to rezone more than 18 acres in Fort Worth’s Riverside area overlooking Oakhurst Scenic Drive, the Trinity River and downtown, with plans to build as many as 400 apartments and townhomes aimed at renters who want to live in or near the central city. D

read more >

Einstein Bagels closing two Tarrant locations

Einstein Bagels is closing two Tarrant County locations, part of a series of 39 closings around the country, according to the company’s owners, JAB Holding Co.

read more >

Dallas developer confirmed to build Walsh Ranch in west Fort Worth

Dallas-based Republic Property Group has been chosen to lead Walsh Ranch development as the 7,200-acre residential community takes shape in west Fort Worth.

read more >

Berkshire Hathaway company acquires Fort Worth firm

M&M Manufacturing, a producer of sheet metal products for the air distribution and ventilation market based in Fort Worth, has been acquired by MiTek Industries Inc., a subsidiary of Warren Buffett’s Berkshire Hathaway Inc.,

read more >

 

Nicox, with Fort Worth operations, to acquire Aciex Therapeutics of Boston

Nicox S.A., an international ophthalmic company whose United States operations are based in Fort Worth, will acquire Aciex Therapeutics Inc., a private ophthalmic development pharmaceutical company in Boston, on a cash-free, debt-free basis through a reverse triangular merger.
Under terms of the proposed acquisition, Aciex shareholders will receive an upfront payment of $65 million in the form of 20,627,024 newly issued Nicox shares, plus contingent value rights giving right to shares for a potential additional value of up to $55 million.


The transaction will broaden and strengthen Nicox’s therapeutic development pipeline, which would include two phase 3 candidates, one being developed by Nicox’s partner Bausch + Lomb.
Aciex brings a near-term pipeline of ophthalmic therapeutic product candidates, including one for allergic conjunctivitis.
Aciex was founded in 2007 with technology licensed from Afferent Therapeutics LLC, a spin-out from Ora Inc.


The completion of the acquisition is subject to the approval of Nicox’s shareholders and other customary conditions.
Nicox was founded in 1996 and is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets, and an expanding international presence through partners. The company had a market cap of $271 million as of Feb. 28, 2014, and cash position of $86.1 million as of Sept. 30, 2013. Nicox employs about 134 people worldwide.
Nicox S.A. is listed on Euronext Paris.

Betty Dillard
bdillard@bizpress.net
 

< back

Email   email
hide
Catch
How 'bout them Cowboys?